Leaders in Partnering, M&A Deals and Strategic Alliances

PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes it uniquely placed to support business in all aspects of deal-making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

What Our Clients Say

“This clinical trial collaboration with MSD holds great significance for WMBIO as it allows us to evaluate a first-in-class drug with a novel mechanism in combination with KEYTRUDA. We engaged PharmaVentures as our advisors for this collaboration and continue to work with them in partnering for WM-A1-3389.”

Dong-Hoon Jin, CEO of Wellmarker Bio, S. Korea

“I feel I made an excellent choice in PharmaVentures to serve as my exclusive advisors for the sale of the Company. They have a comprehensive understanding of our business and helped me identify the ideal partner that shared our strategic vision…I truly value the professional advice and the expert guidance made through every step of the process which enabled us to close the transaction to the satisfaction of all stakeholders.”

Sabine Husmann-Holloway, Co-Founder & CEO, ERA Consulting Group, UK

“We are pleased to be collaborating with ADC Therapeutics, one of the leading companies in the ADC area. We hope to leverage ADC Therapeutics’ experience with the development and commercialisation of its own ADC ZYNLONTA®. We have been working closely with PharmaVentures for the last few years, during which time PharmaVentures has been supporting our partnering efforts for our OHPAS and PMT platform technologies and our B7-H3 ADC.”

Tae Kyo Park, Founder and CEO of IntoCell, S. Korea

“Delighted to have agreed a long-term partnership with Wellmarker Bio (WMBIO). Thanks for the professional support from Adrian Dawkes and his team at PharmaVentures. This combines the two companies’ expertise and experience to develop novel therapeutics for the benefit of patients.”

Dave Mead, Director of Business Development, Isogenica Ltd, UK

“PharmaVentures has been exceptional throughout the entire process. We greatly appreciated their meticulous care and attention to detail, which is not always found in such collaborations. We look forward to continuing the collaboration with PharmaVentures.”

Paavo Pilv, CEO, GeneCode, Estonia

“[We are] very, very pleased with the result; your report was instrumental……..it was a pleasure working with you on this matter…….your work helped us obtain a good result.”

Partner of US Legal Firm

“We were able to start licensing negotiations on several new products in a very short time period with the assistance of the highly professional and well organized experts from PV.”

Multinational Pharmaceutical Company

“I’ve just spoken with [future client name withheld] commenting to him on the very positive experience we had with you (PharmaVentures) some time ago and frankly telling him that, should we have to repeat a similar experience in the future, we would contact you again without doubt to help us with your advice.”

Owner, EU Pharmaceutical Company

“We have…. retained the services of PharmaVentures ……their contribution has been invaluable….”

CEO, Australian Biotechnology Company

“We have found PharmaVentures extremely valuable and uniquely frank in the way you have advised us…..we feel that you are very much part of our team. We would like to thank you for your efforts.”

CEO, US Corporation (subsidiary of a top Fortune 100 company)

“I was Head of Business Development at [name withheld], Inc. New Jersey, USA. PharmaVentures conducted a highly professional market evaluation study and the company decided to enter the acute care pharmaceutical market in Europe. I have no hesitation in giving PharmaVentures a first class reference.”

Former Head of Business Development, US Pharmaceutical Company, (Currently, Pres.& CEO, US Biotech)

“Why hadn’t we found you guys sooner?”

Co-Founder, Biotech Company

“I was most impressed with the professionalism in evidence at PharmaVentures ….our profound thanks and appreciation, this was a job well done!”

CEO, Canadian Biotech